Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist

By afschroeder • October 23, 2025

Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. J Opioid Manag. 2025 Sep-Oct;21(5):377-387. doi: 10.5055/jom.0958. PMID: 41123260.

Tags: General Internal Medicine, Publications, Veterans Administration

Donna L. Washington, MD, MPH, FACP Appointed Section Chief of General Internal Medicine at the VA Greater Los Angeles Healthcare System

It is with great pleasure that we announce the appointment of Donna L. Washington, MD, MPH, FACP as the incoming section chief of General Internal Medicine at[...]

Effect of Language Interpreter Modalities on Patient Satisfaction and Clinical Workflow: A Pilot Study in a Multidisciplinary Pediatric Craniofacial Clinic

Juang S, Nguyen S, Osman N, Ghodrati K, Reyes C, Maldonado I, Pino J, Duarte M, Halley K, Hendrickson I, Tu M, Peralta JB, Wilhalme[...]

Reframing Opioid Overdose as an Ambulatory Care-Sensitive Condition

Hsu M, Lawrence D, Capone-Newton P, Gelberg L. Reframing Opioid Overdose as an Ambulatory Care-Sensitive Condition. JAMA. 2025 Dec 29. doi: 10.1001/jama.2025.23741. Epub ahead of[...]